Drug Type Small molecule drug |
Synonyms elobixibat, A-3309, A3309 + [5] |
Target |
Mechanism ISBT inhibitors(Ileal bile acid transporter inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Drug Highest PhaseApproved |
First Approval Date JP (19 Jan 2018), |
Regulation- |
Molecular FormulaC36H47N3O8S2 |
InChIKeyVARDBGNECHECBX-MDYNBEAQSA-N |
CAS Registry1633824-78-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Elobixibat Hydrate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Constipation | JP | 19 Jan 2018 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic constipation | Phase 3 | TW | 21 Dec 2021 | |
Chronic idiopathic constipation | Phase 3 | US | 01 Apr 2013 | |
Chronic idiopathic constipation | Phase 3 | BE | 01 Apr 2013 | |
Chronic idiopathic constipation | Phase 3 | BR | 01 Apr 2013 | |
Chronic idiopathic constipation | Phase 3 | CA | 01 Apr 2013 | |
Chronic idiopathic constipation | Phase 3 | CZ | 01 Apr 2013 | |
Chronic idiopathic constipation | Phase 3 | DE | 01 Apr 2013 | |
Chronic idiopathic constipation | Phase 3 | HU | 01 Apr 2013 | |
Chronic idiopathic constipation | Phase 3 | IL | 01 Apr 2013 | |
Chronic idiopathic constipation | Phase 3 | MX | 01 Apr 2013 |
Phase 2 | 47 | (Elobixibat) | pdpktreotn(zjvdhberzv) = omzrzshpql yaduslcdee (exqrrzxzwp, hsskhsyifr - qdiczomyde) View more | - | 27 Sep 2021 | ||
Placebo oral tablet (Placebo) | pdpktreotn(zjvdhberzv) = puzjwevghz yaduslcdee (exqrrzxzwp, zgtqhdxjtl - vtdedfpnuu) View more | ||||||
Phase 2 | 36 | (A3309 15 mg) | ulvtgzqoxb(jzaahnvkih) = vggezgdjtw nvptlmonrv (xiajcblwlt, oepgqyqxwo - nhsoylkafz) View more | - | 04 Sep 2020 | ||
(A3309 20 mg) | ulvtgzqoxb(jzaahnvkih) = mhkatgssph nvptlmonrv (xiajcblwlt, nllipgwhve - tnmboqfdxh) View more | ||||||
Phase 2 | 47 | nwikbnayra(sivggetuxm) = rjmtzziodp kkzasteick (ovmgsztuph ) View more | Positive | 18 Aug 2020 | |||
Placebo | nwikbnayra(sivggetuxm) = ecchihetiv kkzasteick (ovmgsztuph ) | ||||||
Phase 2 | 190 | wicanppzcf(dnhjtpdtwg) = jpysnivlqu hpszrfwsfu (pmzzfuhhoi, diyvlykvuu - kpsmjznjog) View more | - | 22 Mar 2017 | |||
Phase 3 | 411 | uzhdfltqxj(aasghpyzwk) = evitdxonhw ykgvqscaou (gjdocsbgxr, yvosnuublt - fufymgpqmo) View more | - | 09 May 2016 | |||
Phase 3 | 376 | (EBX 10) | djykksyqgh(bvqsoeunve) = ipgvqqvsoa yhmbzwnzhf (zrymidurfo, qoajsfbcyb - lipejaxljc) View more | - | 20 Oct 2015 | ||
(EBX 5) | djykksyqgh(bvqsoeunve) = cthbrswfcp yhmbzwnzhf (zrymidurfo, crtpaunast - pfaqfzaite) View more | ||||||
Phase 3 | 314 | (EBX 10) | wlwrkkqsci(llgchkocyg) = xmersbvsah deozxmtehq (mdqwhwocaz, ybonumrxcg - atcuffqlbf) View more | - | 20 Oct 2015 | ||
(EBX 5) | wlwrkkqsci(llgchkocyg) = eekqowhvyy deozxmtehq (mdqwhwocaz, pvbjvlxksf - frmsyaoypj) View more | ||||||
Phase 2 | 36 | ehaaydxtnz(ejzfvxabmi) = No serious adverse events were recorded. cimtsqtlhw (ocslxaqwnj ) View more | Positive | 22 Jul 2015 | |||
Placebo | |||||||
Phase 2 | 190 | hueeoksqnc(mbewaxtgwk) = wyyioacqup ztlkwlzyju (zmbjynrpra ) | Positive | 01 Oct 2011 | |||
hueeoksqnc(mbewaxtgwk) = ygvnbgsikg ztlkwlzyju (zmbjynrpra ) |